Literature DB >> 14770287

[How is oxcarbazepine different from carbamazpine?].

D Schmidt1, C E Elger.   

Abstract

Oxcarbazepine (OXC, trade names Timox, Trileptal is a new antiepileptic drug (AED) for treatment of mono- and adjunctive therapy of partial seizures with or without secondary generalization for adults and children older than 6 years of age. Although OXC was developed through structural variation of carbamazepine in order to avoid side effects from metabolites, significant differences have emerged between the two drugs. The mechanism of action mainly involves blockade of sodium currents but differs from CBZ by modulating different types of calcium channels. In contrast to CBZ, which is oxidized by the cytochrome P-450 system, OXC undergoes reductive metabolism at its ketomoiety to form MHD, which is glucuronidated and excreted in the urine. Involvement of the hepatic cytochrome P450-dependent enzymes in the metabolism of OXC is minimal. This allows for better combining of OXC with other AEDs such as valproate. In postmarketing experience of over 800,000 patient-years, OXC also showed an advantageous risk-benefit ratio. Oxcarbazepine should be preferred over CBZ and other older AEDs due to its very good efficacy and better side effect profile in children, adolescents, and adults with partial seizures.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14770287     DOI: 10.1007/s00115-003-1658-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  43 in total

1.  First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.

Authors:  R G Dickinson; W D Hooper; P R Dunstan; M J Eadie
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  New drugs for persons with epilepsy.

Authors:  D E Blum
Journal:  Adv Neurol       Date:  1998

3.  Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy.

Authors:  J Rättyä; J Turkka; A J Pakarinen; M Knip; M A Kotila; O Lukkarinen; V V Myllylä; J I Isojärvi
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

4.  Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial.

Authors:  A Beydoun; R C Sachdeo; W E Rosenfeld; G L Krauss; N Sessler; P Mesenbrink; L Kramer; J D'Souza
Journal:  Neurology       Date:  2000-06-27       Impact factor: 9.910

5.  Carbamazepine inhibits L-type Ca2+ channels in cultured rat hippocampal neurons stimulated with glutamate receptor agonists.

Authors:  A F Ambrósio; A P Silva; J O Malva; P Soares-da-Silva; A P Carvalho; C M Carvalho
Journal:  Neuropharmacology       Date:  1999-09       Impact factor: 5.250

6.  The metabolism of 14C-oxcarbazepine in man.

Authors:  H Schütz; K F Feldmann; J W Faigle; H P Kriemler; T Winkler
Journal:  Xenobiotica       Date:  1986-08       Impact factor: 1.908

7.  Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.

Authors:  M Schmutz; F Brugger; C Gentsch; M J McLean; H R Olpe
Journal:  Epilepsia       Date:  1994       Impact factor: 5.864

8.  Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use.

Authors:  Dieter Schmidt; Rajesh Sachdeo
Journal:  Epilepsy Behav       Date:  2000-12       Impact factor: 2.937

Review 9.  Oxcarbazepine: a review of its use in children with epilepsy.

Authors:  Lynne Bang; Karen Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

10.  Possible interaction between oxcarbazepine and an oral contraceptive.

Authors:  P Klosterskov Jensen; V Saano; P Haring; B Svenstrup; G P Menge
Journal:  Epilepsia       Date:  1992 Nov-Dec       Impact factor: 5.864

View more
  2 in total

1.  Effects of oxcarbazepine and carbamazepine on driving ability: a double-blind, randomized crossover trial with healthy volunteers.

Authors:  Yvonne Kaussner; Ramona Kenntner-Mabiala; Sonja Hoffmann; Jan Klatt; Ferenc Tracik; Hans-Peter Krüger
Journal:  Psychopharmacology (Berl)       Date:  2010-03-17       Impact factor: 4.530

Review 2.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.